Cluster Headache Treatment With Rimegepant

Part of paid clinical trials in Rochester, Minnesota.

Sponsor
Mayo Clinic
Study ID
NCT05264714
Phase
PHASE2
Status
Completed

Conditions

  • Cluster Headache

Eligibility Criteria

Sex
ALL
Age
18 Years - N/A
Healthy Volunteers
Not accepted

Interventions

  • Rimegepant — DRUG
    150 mg oral disintegrating tablet every other day for one week

Study Details

The purpose of this research is to explore the efficacy of rimegepant as a preventative therapy for cluster headache.

Key Dates

Start date
Sep 7, 2022
Status verified
Jan 2026
Primary completion
Dec 31, 2025
Completion
Dec 31, 2025

Study Design

Enrollment
20 participants (actual)
Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT

Arms

  • Experimental: Cluster Headache Subjects
    Subjects with cluster headaches will track their headaches for a one-week baseline headache diary. After establishing the baseline headache frequency, severity, and abortive medicine use, subjects will be asked to start their first dose of rimegepant with their next moderate to severe cluster headache.

Primary Outcome Measure

Change in weekly frequency of cluster headache attacks [ Time Frame: Baseline, week of treatment (days 1-7) ]

Locations (1)

FacilityCityStateZIPSite coordinators
Mayo Clinic RochesterRochesterMinnesota55905-

Find similar trials in Rochester, MN

By research site
Mayo Clinic Rochester· Rochester, MN

Related Studies